CA3083122A1 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds - Google Patents

Sulfone pyridine alkyl amide-substituted heteroaryl compounds Download PDF

Info

Publication number
CA3083122A1
CA3083122A1 CA3083122A CA3083122A CA3083122A1 CA 3083122 A1 CA3083122 A1 CA 3083122A1 CA 3083122 A CA3083122 A CA 3083122A CA 3083122 A CA3083122 A CA 3083122A CA 3083122 A1 CA3083122 A1 CA 3083122A1
Authority
CA
Canada
Prior art keywords
substituted
amino
alkyl
carboxamide
nr11r11
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3083122A
Other languages
English (en)
French (fr)
Inventor
Chunjian Liu
Michael G. Yang
Zili Xiao
Ling Chen
Ryan M. MOSLIN
John S. Tokarski
David S. Weinstein
Stephen T. Wrobleski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA3083122A1 publication Critical patent/CA3083122A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3083122A 2017-11-21 2018-11-19 Sulfone pyridine alkyl amide-substituted heteroaryl compounds Pending CA3083122A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589165P 2017-11-21 2017-11-21
US62/589,165 2017-11-21
PCT/US2018/061726 WO2019103952A1 (en) 2017-11-21 2018-11-19 Sulfone pyridine alkyl amide-substituted heteroaryl compounds

Publications (1)

Publication Number Publication Date
CA3083122A1 true CA3083122A1 (en) 2019-05-31

Family

ID=65036887

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3083122A Pending CA3083122A1 (en) 2017-11-21 2018-11-19 Sulfone pyridine alkyl amide-substituted heteroaryl compounds

Country Status (20)

Country Link
US (4) US11021462B2 (enExample)
EP (1) EP3713930A1 (enExample)
JP (2) JP7258903B2 (enExample)
KR (1) KR102702228B1 (enExample)
CN (1) CN111315737B (enExample)
AR (1) AR113895A1 (enExample)
AU (3) AU2018371010C1 (enExample)
BR (1) BR112020009606A2 (enExample)
CA (1) CA3083122A1 (enExample)
CL (1) CL2020001338A1 (enExample)
CO (1) CO2020006139A2 (enExample)
EA (1) EA202091269A1 (enExample)
IL (1) IL274816B2 (enExample)
MX (1) MX2020005210A (enExample)
MY (1) MY202167A (enExample)
PE (1) PE20211461A1 (enExample)
SG (1) SG11202004592TA (enExample)
TW (1) TWI776994B (enExample)
WO (1) WO2019103952A1 (enExample)
ZA (1) ZA202003717B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7258903B2 (ja) * 2017-11-21 2023-04-17 ブリストル-マイヤーズ スクイブ カンパニー スルホンピリジンアルキルアミド置換ヘテロアリール化合物
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
EP4007757B1 (en) 2019-08-01 2025-09-10 Sperogenix Therapeutics Limited Heterocyclic compounds as kinase inhibitor and uses thereof
CN115160297B (zh) * 2020-12-22 2023-03-31 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
JP2024510274A (ja) 2021-03-16 2024-03-06 アンルイ バイオメディカル テクノロジー (グァンヂョウ) カンパニー リミテッド アミノヘテロアリール化合物および組成物
US20240182429A1 (en) * 2021-03-30 2024-06-06 Zhejiang Wenda Pharma Technology Ltd. Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use
US20250066322A1 (en) * 2021-05-14 2025-02-27 Bristol-Myers Squibb Company Substituted heterocyclic compounds
CN115466289A (zh) * 2021-06-11 2022-12-13 爱科诺生物医药(香港)有限公司 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用
CN115724830A (zh) * 2021-08-31 2023-03-03 浙江文达医药科技有限公司 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法
TW202339749A (zh) 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Tyk2抑制劑及其組合物和方法
CN116693449A (zh) * 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
CN117257752A (zh) * 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 药物组合物及其用途
CN120303268A (zh) * 2022-12-16 2025-07-11 津药生物科技(天津)有限公司 新型含杂环取代的丙烯酸衍生物及其用途
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013104573A1 (en) * 2012-01-10 2013-07-18 F. Hoffmann-La Roche Ag Pyridazine amide compounds and their use as syk inhibitors
HK1211024A1 (en) * 2012-10-19 2016-05-13 霍夫曼-拉罗奇有限公司 Inhibitors of syk
UY35126A (es) 2012-11-08 2014-05-30 Bristol Myers Squibb Co Ojo es alfa
BR112015010244A8 (pt) * 2012-11-08 2019-10-01 Bristol Myers Squibb Co compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso
AR094537A1 (es) * 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
MX375752B (es) * 2013-12-05 2025-03-06 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
MA48602A (fr) 2016-12-13 2020-03-18 Bristol Myers Squibb Co Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha
JP7258903B2 (ja) * 2017-11-21 2023-04-17 ブリストル-マイヤーズ スクイブ カンパニー スルホンピリジンアルキルアミド置換ヘテロアリール化合物

Also Published As

Publication number Publication date
JP7258903B2 (ja) 2023-04-17
MX2020005210A (es) 2020-08-20
AU2023255024B2 (en) 2025-05-01
WO2019103952A1 (en) 2019-05-31
AU2018371010C1 (en) 2024-09-26
CN111315737A (zh) 2020-06-19
EA202091269A1 (ru) 2020-08-07
JP2023098942A (ja) 2023-07-11
NZ765438A (en) 2024-11-29
US20190152948A1 (en) 2019-05-23
US11787779B2 (en) 2023-10-17
CN111315737B (zh) 2024-06-18
US20250304555A1 (en) 2025-10-02
US11021462B2 (en) 2021-06-01
US12365667B2 (en) 2025-07-22
IL274816B2 (en) 2023-12-01
AU2022228101B2 (en) 2023-08-03
AU2023255024A1 (en) 2023-11-16
AU2018371010A1 (en) 2020-07-02
IL274816B1 (en) 2023-08-01
US20210253554A1 (en) 2021-08-19
MY202167A (en) 2024-04-12
JP2021504443A (ja) 2021-02-15
US20240002364A1 (en) 2024-01-04
ZA202003717B (en) 2022-01-26
IL274816A (en) 2020-07-30
PE20211461A1 (es) 2021-08-05
JP7490107B2 (ja) 2024-05-24
KR102702228B1 (ko) 2024-09-02
SG11202004592TA (en) 2020-06-29
TW201925187A (zh) 2019-07-01
AR113895A1 (es) 2020-06-24
EP3713930A1 (en) 2020-09-30
TWI776994B (zh) 2022-09-11
AU2018371010B2 (en) 2022-06-09
CO2020006139A2 (es) 2020-05-29
BR112020009606A2 (pt) 2020-11-03
AU2022228101A1 (en) 2022-09-29
KR20200089706A (ko) 2020-07-27
CL2020001338A1 (es) 2020-09-25

Similar Documents

Publication Publication Date Title
AU2022228101B2 (en) Sulfone pyridine alkyl amide-substituted heteroaryl compounds
US11597721B2 (en) Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFNα responses
IL282840B1 (en) Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
EP4143180A1 (en) Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators
EP3917912B1 (en) Amide-disubstituted pyridine or pyridazine compounds
EP3555111B1 (en) Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses
EP4337650A1 (en) Substituted heterocyclic compounds
CN117279906A (zh) 经取代的杂环化合物
EA046543B1 (ru) Амидзамещенные гетероциклические соединения
EA041710B1 (ru) Сульфон-, пиридин-, алкил-, амидзамещенные гетероарильные соединения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220803

EEER Examination request

Effective date: 20220803

EEER Examination request

Effective date: 20220803

EEER Examination request

Effective date: 20220803

EEER Examination request

Effective date: 20220803

EEER Examination request

Effective date: 20220803